Rhabdomyolysis in a cardiac transplant recipient due to verapamil interaction with simvastatin and cyclosporin treatment [3];Rhabdomyolyse liée à l'ajout du vérapamil à un traitement par simvastatine et ciclosporine chez un patient transplanté cardiaque

Therapie

Volumn 58, Issue 2, 2003, Pages 168-170

  Chiffoleau, Anne ^a   Trochu, Jean Noël ^b   Veyrac, Gwenaëlle ^a   Petit, Thierry ^b   Abadie, Patrick ^c   Bourin, Michel ^a   Jolliet, Pascale ^a  

^a INSTITUT DE BIOLOGIE   (France)

^b CHU de Nantes   (France)

^c Clinique Le Val d'Olonne   (France)

Author keywords

Cyclosporin; CYP 450, adverse effect; Heart transplantation; Interaction; Rhabdomyolysis; Simvastatin; Verapamil

Indexed keywords

ACETYLSALICYLIC ACID; ALDACTAZINE; CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450; LEVOTHYROXINE; LYSINE ACETYLSALICYLATE; PREDNISOLONE 3 SULFOBENZOATE; SIMVASTATIN; VALPROIC ACID; VERAPAMIL;

ADULT; CASE REPORT; EPILEPSY; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; PRIORITY JOURNAL; RHABDOMYOLYSIS;

EID: 0043157295     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2003026     Document Type: Letter

References (13)

1. Auer J, Eber B. A clinical focus on statins. Curr Opin Investig Drugs 2001; 2: 382-8
2. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002; 128: 159-68
3. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-COA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-107
4. Langer T, Levy RI. Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 1968; 279: 856-8
5. Igel M, Sudhop T, Von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3 methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001; 57: 357-64
6. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-COA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-70
7. Afssaps: Le point sur le risque musculaire des statines [online]. Sécurité sanitaire et vigilances, 4 juin 2002. Available from URL: http//www.afssaps.sante.fr
8. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl 2002; 3: 35-40
9. Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51: 461-70
10. Kanathur N, Mathai MG, Byrd RP, et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94: 339-41
11. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-82
12. Kusus M, Stapleton DD, Lertora JJ, et al. Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci 2000; 320: 394-7
13. Bégaud B, Evreux JC, Jouglard J, et al. Imputabilité des effets inattendus ou toxiques des médicaments: actualisation de la méthode utilisée en France. Thérapie 1985; 40: 111-8